|
2024 Journal Article A novel inhibitor of class IIa histone deacetylases attenuates collagen‐induced arthritisPoon, Eunice K., Liu, Ligong, Wu, Kai‐Chen, Lim, Junxian, Sweet, Matthew J., Lohman, Rink‐Jan, Iyer, Abishek and Fairlie, David P. (2024). A novel inhibitor of class IIa histone deacetylases attenuates collagen‐induced arthritis. British Journal of Pharmacology, 181 (23), 4804-4821. doi: 10.1111/bph.17306 |
|
2024 Book Chapter Integration of dendrimer-based delivery technologies with computational pharmaceutics and their potential in the era of nanomedicineTupally, Karnaker Reddy, Seal, Prasenjit, Pandey, Preeti, Lohman, Rink-Jan, Smith, Sean, Ouyang, Defang and Parekh, Haredra (2024). Integration of dendrimer-based delivery technologies with computational pharmaceutics and their potential in the era of nanomedicine. Exploring computational pharmaceutics - AI and modeling in Pharma 4.0. (pp. 328-378) edited by Defang Ouyang. Hoboken, NJ, United States: Wiley. doi: 10.1002/9781119987260.ch10 |
|
2023 Conference Publication Bivalent kappa-selective opioid peptides with enhanced metabolic stability and potencySaifuddin, D., Lohman, R.-J., Tupally, K., Parekh, H. and Cabot, P. (2023). Bivalent kappa-selective opioid peptides with enhanced metabolic stability and potency. 81st FIP World Congress Of Pharmacy And Pharmaceutical Sciences, Brisbane, QLD Australia, 24-28 September 2023. PKP Publishing. |
|
2023 Journal Article Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venomGalante, Priscilla, Campos, Gabriel A. A., Moser, Jacqueline C. G., Martins, Danubia B., Dos Santos Cabrera, Marcia P., Rangel, Marisa, Coelho, Luiza C., Simon, Karina S., Amado, Veronica M., de A. I. Muller, Jessica, Koehbach, Johannes, Lohman, Rink-Jan, Cabot, Peter J., Vetter, Irina, Craik, David J., Toffoli-Kadri, Monica C., Monge-Fuentes, Victoria, Goulart, Jair T., Schwartz, Elisabeth F., Silva, Luciano P., Bocca, Anamelia L. and Mortari, Márcia R (2023). Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom. Scientific Reports, 13 (1) 12491, 1-15. doi: 10.1038/s41598-023-38828-w |
|
2023 Journal Article Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapyLohman, Rink-Jan, Tupally, Karnaker Reddy, Kandale, Ajit, Cabot, Peter J and Parekh, Harendra S (2023). Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy. Frontiers in Pharmacology, 14 1150313, 1150313-14. doi: 10.3389/fphar.2023.1150313 |
|
2022 Journal Article Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapyLohman, Rink-Jan, Tupally, Karnaker Reddy, Kandale, Ajit, Cabot, Peter J. and Parekh, Harendra S. (2022). Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy. British Journal of Pharmacology, 180 (1), 129-129. doi: 10.1111/bph.15862 |
|
2022 Journal Article Fabrication and Characterization of Clozapine Nanoemulsion Sol–Gel for Intranasal AdministrationTan, Madeleine S. A., Pandey, Preeti, Lohman, Rink-Jan, Falconer, James R., Siskind, Dan J. and Parekh, Harendra S. (2022). Fabrication and Characterization of Clozapine Nanoemulsion Sol–Gel for Intranasal Administration. Molecular Pharmaceutics, 19 (11), 4055-4066. doi: 10.1021/acs.molpharmaceut.2c00513 |
|
2021 Conference Publication Novel opioid peptides as allosteric modulators of nociceptionSaifuddin, Danial, Lohman, Rink-Jan, Tupally, Karnaker Reddy, Parekh, Harendra S. and Cabot, Peter J. (2021). Novel opioid peptides as allosteric modulators of nociception. ASMR medical research week: Queensland virtual symposium, Online, 9-10 June 2021. |
|
2020 Journal Article Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibitionKennedy, Amanda J., Sundström, Linda, Geschwindner, Stefan, Poon, Eunice K. Y., Jiang, Yuhong, Chen, Rongfeng, Cooke, Rob, Johnstone, Shawn, Madin, Andrew, Lim, Junxian, Liu, Qingqi, Lohman, Rink-Jan, Nordqvist, Anneli, Fridén-Saxin, Maria, Yang, Wenzhen, Brown, Dean G., Fairlie, David P. and Dekker, Niek (2020). Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition. Communications Biology, 3 (1) 782, 782. doi: 10.1038/s42003-020-01504-0 |
|
2020 Journal Article Potent thiophene antagonists of human complement C3a receptor with anti-inflammatory activityRowley, Jessica A., Reid, Robert C., Poon, Eunice K. Y., Wu, Kai-Chen, Lim, Junxian, Lohman, Rink-Jan, Hamidon, Johan K., Yau, Mei-Kwan, Halili, Maria A., Durek, Thomas, Iyer, Abishek and Fairlie, David P. (2020). Potent thiophene antagonists of human complement C3a receptor with anti-inflammatory activity. Journal of Medicinal Chemistry, 63 (2) acs.jmedchem.9b00927, 529-541. doi: 10.1021/acs.jmedchem.9b00927 |
|
2020 Journal Article High cell permeability does not predict oral bioavailability for analogues of cyclic heptapeptide sanguinamide ANielsen, Daniel S., Lohman, Rink-Jan, Hoang, Huy N., Fairlie, David P. and Hill, Timothy A. (2020). High cell permeability does not predict oral bioavailability for analogues of cyclic heptapeptide sanguinamide A. Australian Journal of Chemistry, 73 (4), 344-351. doi: 10.1071/ch19479 |
|
2019 Journal Article Mirror image pairs of cyclic hexapeptides have different oral bioavailabilities and metabolic stabilitiesLohman, Rink-Jan, Nielsen, Daniel S., Kok, W. Mei, Hoang, Huy N., Hill, Timothy A. and Fairlie, David P. (2019). Mirror image pairs of cyclic hexapeptides have different oral bioavailabilities and metabolic stabilities. Chemical Communications, 55 (89), 13362-13365. doi: 10.1039/c9cc06234c |
|
2019 Journal Article Protease-activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidneyMa, Frank Y., Han, Yingjie, Ozols, Elyce, Chew, Phyllis, Vesey, David A., Gobe, Glenda C., Morais, Christudas, Lohman, Rink-Jan, Suen, Jacky Y., Johnson, David W., Fairlie, David P. and Nikolic-Paterson, David J. (2019). Protease-activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidney. Nephrology, 24 (9) nep.13635, 983-991. doi: 10.1111/nep.13635 |
|
2019 Journal Article Minocycline prevents the development of mechanical allodynia in mouse models of vincristine-induced peripheral neuropathyStarobova, H., Mueller, A., Allavena, R., Lohman, R. J., Sweet, M. J. and Vetter, I. (2019). Minocycline prevents the development of mechanical allodynia in mouse models of vincristine-induced peripheral neuropathy. Frontiers in Neuroscience, 13 (JUN) 653, 653. doi: 10.3389/fnins.2019.00653 |
|
2019 Journal Article Pharmacological inhibition of protease-activated receptor-2 reduces crescent formation in rat nephrotoxic serum nephritisHan, Yingjie, Tian, Lifang, Ma, Frank, Tesch, Greg, Vesey, David A., Gobe, Glenda C., Lohman, Rink-Jan, Morais, Christudas, Suen, Jacky Y., Fairlie, David P. and Nikolic-Paterson, David J. (2019). Pharmacological inhibition of protease-activated receptor-2 reduces crescent formation in rat nephrotoxic serum nephritis. Clinical and Experimental Pharmacology and Physiology, 46 (5) 1440-1681.13077, 456-464. doi: 10.1111/1440-1681.13077 |
|
2019 Journal Article Structure-activity relationships of wollamide cyclic hexapeptides with activity against drug-resistant and intracellularKhalil, Zeinab G., Hill, Timothy A., De Leon Rodriguez, Luis M., Lohman, Rink-Jan, Hoang, Huy N., Reiling, Norbert, Hillemann, Doris, Brimble, Margaret A., Fairlie, David, Blumenthal, Antje and Capon, Robert J. (2019). Structure-activity relationships of wollamide cyclic hexapeptides with activity against drug-resistant and intracellular. Antimicrobial Agents and Chemotherapy, 63 (3) e01773-18. doi: 10.1128/AAC.01773-18 |
|
2018 Conference Publication PAR-2 does not contribute to tubular damage or renal fibrosis in the obstructed kidneyHan, Y., Ma, F., Ozols, E., Chew, P., Vesey, D., Gobe, G., Morais, C., Lohman, R., Suen, J., Fairlie, D. and Nikolic-Paterson, D. (2018). PAR-2 does not contribute to tubular damage or renal fibrosis in the obstructed kidney. 54th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (ANZSN), Sydney, Australia, 8–12 September 2018. Richmond, VIC, Australia: Wiley-Blackwell. doi: 10.1111/nep.13441 |
|
2017 Journal Article Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3aLohman, Rink-Jan, Hamidon, Johan K., Reid, Robert C., Rowley, Jessica A., Yau, Mei-Kwan, Halili, Maria A., Nielsen, Daniel S., Lim, Junxian, Wu, Kai-Chen, Loh, Zhixuan, Do, Anh, Suen, Jacky Y., Iyer, Abishek and Fairlie, David P. (2017). Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a. Nature Communications, 8 (1) 351, 351. doi: 10.1038/s41467-017-00414-w |
|
2017 Journal Article An HDAC6 inhibitor confers protection and selectively inhibits B-cell infiltration in DSS-induced colitis in miceDo, Anh, Reid, Robert C., Lohman, Rink-Jan, Sweet, Matthew J., Fairlie, David P. and Iyer, Abishek (2017). An HDAC6 inhibitor confers protection and selectively inhibits B-cell infiltration in DSS-induced colitis in mice. The Journal of Pharmacology and Experimental Therapeutics, 360 (1), 140-151. doi: 10.1124/jpet.116.236711 |
|
2016 Journal Article Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2Lieu, T., Savage, E., Zhao, P., Edgington-Mitchell, L., Barlow, N., Bron, R., Poole, D. P., Mclean, P., Lohman, R. -J., Fairlie, D. P. and Bunnett, N. W. (2016). Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2. British Journal of Pharmacology, 173 (18), 2752-2765. doi: 10.1111/bph.13554 |
